Ranbaxy gains over 5% on US FDA nod
27/06/2014 11:05
Shares of Ranbaxy rose over 5 per cent in early trade on Bombay Stock Exchange (BSE) on reports that the drug maker has received the US Food and Drug Administration (US FDA)'s approval to sell a generic version of Novartis's hypertension medicine, Diovan. The shares of company rose as much as 5.64 per cent to trade at Rs 498.35 a piece on the BSE. However, shares of the company rose 5.29 per cent to Rs 498.15 a piece on National Stock Exchange. Meanwhile, the broader benchmark Sensex was quoting at 25,192.50, up 129.83 points or 0.52 per cent at 11.00 hours.
27/06/2014 11:05
Shares of Ranbaxy rose over 5 per cent in early trade on Bombay Stock Exchange (BSE) on reports that the drug maker has received the US Food and Drug Administration (US FDA)'s approval to sell a generic version of Novartis's hypertension medicine, Diovan. The shares of company rose as much as 5.64 per cent to trade at Rs 498.35 a piece on the BSE. However, shares of the company rose 5.29 per cent to Rs 498.15 a piece on National Stock Exchange. Meanwhile, the broader benchmark Sensex was quoting at 25,192.50, up 129.83 points or 0.52 per cent at 11.00 hours.
